Adicet Bio (ACET)
(Delayed Data from NSDQ)
$0.67 USD
-0.02 (-2.19%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.66 -0.01 (-1.58%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACET 0.67 -0.02(-2.19%)
Will ACET be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACET based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACET
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
ACET: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ACET
Adicet Bio (ACET) Advances Phase 1 Trial for Autoimmune Treatment | ACET Stock News
Adicet Bio doses first patient in second cohort of ADI-001 trial
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical ...
Adicet Bio (ACET) Receives Buy Rating from HC Wainwright & Co. | ACET Stock News
ACET Stock Potential Boosted by New Analyst Coverage | ACET Stock News